Louisville, Kentucky, May 8, 2026, 04:18 EDT
- Humana cut its 2026 GAAP EPS outlook to at least $8.36, down from the previous floor of $8.89, but left its adjusted EPS forecast unchanged at a minimum of $9.00.
- The stock ended up at $247.12. That’s well above the $212.87 fair value estimated by Simply Wall St’s model, hinting at a possible 16.1% drop from that level.
- Medicare Advantage is in the spotlight—private insurers juggling tight margins as they face pressure from funding issues, rising medical costs, and shrinking quality-rating bonuses.
Humana Inc. shares have been on a tear—up 25.35% in the past 30 days, and 27.42% over the last 90, per Simply Wall St—even as the Medicare-focused insurer lowered its 2026 profit guidance. The latest rally arrives despite Humana cutting its full-year GAAP EPS outlook.
The focus has shifted beyond Humana’s first-quarter numbers. Investors are now trying to gauge if the company can restore Medicare Advantage margins as quality rating cuts trim bonus payments and a 2027 U.S. government payment bump likely won’t keep pace with rising medical costs.
Humana’s first-quarter revenue climbed to $39.65 billion, a jump from $32.11 billion this time last year. Net income attributable to the company edged down, landing at $1.19 billion compared with $1.24 billion previously. Diluted EPS also moved lower, dropping to $9.83 from $10.30. Adjusted EPS came in at $10.31, down from $11.58.
The company reported its benefit ratio climbed to 89.4%, compared with 87.0% a year ago. In the insurance segment, that same ratio was 89.4%, up from 87.4%. The increase points to the impact from Star Ratings and higher early medical costs tied to newer Medicare Advantage members.
Humana President and CEO Jim Rechtin called it a “solid start to the year,” pointing to gains in both customer experience and care quality. The company stuck with its forecast for 2026, still projecting individual Medicare Advantage membership growth of roughly 25% over 2025. Humana Health Policy Center
Humana trimmed its GAAP EPS outlook to at least $8.36, down from $8.89, but left its adjusted EPS forecast unmoved at $9.00 or more. The company noted that the adjusted figure still bakes in a year-on-year drop, blaming the hit on weaker Medicare Star Ratings—important quality marks that determine federal bonus payments.
Analysts struck a wary tone after the update. “HUM has several signals that the back-half of the year could be difficult to manage,” Cantor’s Sarah James told Reuters. Morningstar’s Julie Utterback pointed out that investors likely expected Humana to lift its 2026 outlook, especially given the strong start. Reuters
Capital returns provide a bit of a cushion, though they hardly put the valuation debate to rest. Humana bought back 564,400 shares during the first quarter, paying an average of $182.13 per share. As of April 28, $2.72 billion in buyback capacity remained on the books.
Valuation signals are sending mixed messages. According to Simply Wall St’s top-watched Humana storyline, fair value comes in at $212.87—well under the stock’s latest close of $247.12. Still, they point out Humana’s price/earnings ratio sits at 26.3, which trails the peer group average of 32.4, despite landing above the broader U.S. healthcare sector average of 22.4.
There’s also the squeeze from competition. According to Reuters, Humana and its peers—UnitedHealth Group’s UnitedHealthcare and Aetna under CVS Health—could defend their margins by trimming benefits or quitting markets. Medicare Advantage brings in 80% of Humana’s revenue; for Aetna, it’s 33%, and just 12% at UnitedHealthcare.
Still, there’s a danger in slashing too many perks. Humana could shield its margins by paring back on dental, vision, fitness, or transportation add-ons. But pulling those benefits risks pushing members away—or drawing unwanted political heat, with Medicare Advantage sign-ups set to kick off in October, just as the U.S. midterms approach.
“The practical reality is, all product, if priced appropriately, is good product,” Rechtin told Reuters, adding that Humana is set to review its portfolio and adjust pricing as needed. For investors, it comes down to a narrow bet: shares are climbing on recovery optimism, but earnings remain lashed to a tough Medicare Advantage reset. Reuters
